2023
Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial
Greene S, Velazquez E, Anstrom K, Clare R, DeWald T, Psotka M, Ambrosy A, Stevens G, Rommel J, Alexy T, Ketema F, Kim D, Desvigne-Nickens P, Pitt B, Eisenstein E, Mentz R, Investigators O. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. Circulation 2023, 148: 124-134. PMID: 37212600, PMCID: PMC10524905, DOI: 10.1161/circulationaha.123.064842.Peer-Reviewed Original ResearchConceptsPatient Health Questionnaire-2Prespecified secondary end pointsQuality of lifeEffects of torsemideSecondary end pointsHeart failurePatient-reported outcomesKansas City Cardiomyopathy Questionnaire clinical summary scoreNew York Heart Association classPatient Health Questionnaire-2 scoreEnd pointQuestionnaire-2Loop diuretic agentsLoop diuretic useProportion of patientsBaseline health statusClinical summary scoreEjection fraction phenotypeSignificant differencesDiuretic strategyTorsemide groupCause hospitalizationCause mortalityDiuretic usePrimary therapy
2016
Implementing a Continuous Quality Improvement Program in a High-Volume Clinical Echocardiography Laboratory
Samad Z, Minter S, Armour A, Tinnemore A, Sivak JA, Sedberry B, Strub K, Horan SM, Harrison JK, Kisslo J, Douglas PS, Velazquez EJ. Implementing a Continuous Quality Improvement Program in a High-Volume Clinical Echocardiography Laboratory. Circulation Cardiovascular Imaging 2016, 9: e003708. PMID: 26957220, DOI: 10.1161/circimaging.115.003708.Peer-Reviewed Original ResearchMeSH KeywordsAortic ValveAortic Valve StenosisCardiac CatheterizationCritical PathwaysEchocardiography, DopplerFeasibility StudiesHemodynamicsHospitals, High-VolumeHumansObserver VariationPatient Care TeamPractice Patterns, Physicians'Predictive Value of TestsProgram EvaluationProspective StudiesQuality ImprovementQuality Indicators, Health CareReproducibility of ResultsSeverity of Illness IndexWorkflowConceptsAortic stenosisCatheterization dataContinuous quality improvementMean gradientAortic valve mean gradientCQI teamClinical echocardiography laboratoryGreater aortic stenosisProportion of patientsReferral of patientsPrimary outcome measureContinuous quality improvement programQuality Improvement ProgramAortic gradientCardiac catheterizationEchocardiographic diagnosisEchocardiography studyPractice patternsInvasive studiesOutcome measuresEchocardiography laboratoryValve hemodynamicsSecond sonographerCatheterizationCQI program
2015
Temporal Trends in Disease Severity and Predicted Surgical Risk at the Time of Referral for Echocardiography in Patients Diagnosed with Aortic Stenosis
Ersboll M, Samad Z, Al Enezi F, Kisslo J, Schulte PJ, Shaw LK, Køber L, Harrison JK, Bashore T, Brennan M, Velazquez EJ. Temporal Trends in Disease Severity and Predicted Surgical Risk at the Time of Referral for Echocardiography in Patients Diagnosed with Aortic Stenosis. Critical Pathways In Cardiology A Journal Of Evidence-Based Medicine 2015, 14: 103-109. PMID: 26214813, DOI: 10.1097/hpc.0000000000000048.Peer-Reviewed Original ResearchConceptsSevere aortic stenosisProportion of patientsAortic stenosisSurgical riskHigh-risk aortic valve replacementDisease severityHealth care resource planningAortic valve replacementCalcific aortic stenosisHeart valve surgeryTime of referralTertiary hospital centerNumber of patientsNative aortic valveDuke University HospitalLogistic EuroSCOREValve surgeryValve replacementMedian ageReferral patternsUniversity HospitalAortic valveHospital CenterPatientsReferral
2006
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
Reed SD, McMurray JJ, Velazquez EJ, Schulman KA, Califf RM, Kober L, Maggioni AP, Van de Werf F, White HD, Diaz R, Mareev V, Murin J, Committees and Investigators F. Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial. American Heart Journal 2006, 152: 500-508. PMID: 16923421, DOI: 10.1016/j.ahj.2006.02.032.Peer-Reviewed Original ResearchConceptsHigh-risk patientsAcute myocardial infarctionMyocardial infarctionReperfusion therapyBaseline characteristicsVALIANT trialLeft ventricular systolic dysfunctionTime of MIAcute Myocardial Infarction trialSafety of captoprilMyocardial Infarction trialPatient baseline characteristicsUse of aspirinVentricular systolic dysfunctionProportion of patientsCare of patientsEvidence-based therapiesMultivariable regression modelsSystolic dysfunctionHeart failureTrial populationKey treatmentPatientsInternational trialInternational guidelines